Andere talen Precigen, Inc.

Aandelen

PGEN

US74017N1054

Vertraagde tijd Nasdaq Andere beurzen 19:53:57 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,41 ^USD	+0,71%		+6,02%	+5,22%

24/04	Precigen, Inc. presenteert laat abstract voor gegevens van de cruciale Fase 2-studie voor PRGN-2012 AdenoVerse immunotherapie	CI
22/03	Aandelen Precigen dalen na downgrade van JPMorgan	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting	25/04
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	24/04
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th	28/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Precigen Shares Fall After Downgrade From JPMorgan	22/03
Precigen Reports Full Year 2023 Financial Results and Business Updates	20/03
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
North American Morning Briefing : Stock Futures -2-	19/03
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	12/03
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th	05/03
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe	16/01
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16/01
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16/01
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference	09/01
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference	18/12
Precigen to Participate in the JMP Securities Hematology and Oncology Summit	29/11
Precigen Q3 Net Loss Widens, Revenue Falls	09/11
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Earnings Flash (PGEN) PRECIGEN Posts Q3 Revenue $1.4M	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Precigen, Inc.

Aandelen

PGEN

US74017N1054

Andere talen

Filters